Association of serum pentraxin 3 levels with comorbidities in acute ischaemic stroke patients

Filiz Demirdöğen

Makale detayları

Association of serum pentraxin 3 levels with comorbidities in acute ischaemic stroke patients

Yazarlar:

Filiz Demirdöğen

Yayıncı:

MediHealth Academy Yayıncılık

Ana Başlıklar:

Otonom Sinir Sistemi

Dergi:

Anatolian Current Medical Journal Vol.7 Issue 3, pp.358-362

Belge Tipi:

Makale

Yayın Tarihi:

5/2025

Belge Dili:

İngilizce

Document ID (Org No.):

2001349426

pISSN:

2718-0115

Anahtar kelimeler:

Özet:

 Aims: Pentraxin 3 PTX3, an indicator of the inflammatory process, is an acute-phase protein AP with biphasic effect. In the present study, the relationship between PTX3 levels and stroke risk factors in stroke patients were analyzed. Methods: Acute stroke patients n56 were diagnosed using imaging techniques and clinical examination along with and their laboratory results. The control group consisted of thirty healthy individuals. Blood samples of the patient group were obtained within the first 24 hours of stroke onset. Serum pentraxin levels of both groups were analyzed and their relationship with stroke risk factors evaluated. Results: A total of 86 people, 56 stroke patients and 30 healthy controls were included in the present study. Out of the participants, in both groups, 50 were female p1.000. No significant difference was determined between the groups in terms of age p0.226. The pentraxin value in the patient group was significantly lower than that in the control group p0.003. No significant difference between gender and presence of comorbidities in terms of PTX3 value p0.05 were present. Likewise, no significant correlation could be established between PTX3 value and National Institutes of Health Stroke Scale NIHSS and age in the patient group. Conclusion: Serum PTX3 can be used as a biomarker in acute stroke patients. However, it cannot be used as a predicator in determining prognosis during the acute period.

 Aims: Pentraxin 3 PTX3, an indicator of the inflammatory process, is an acute-phase protein AP with biphasic effect. In the present study, the relationship between PTX3 levels and stroke risk factors in stroke patients were analyzed. Methods: Acute stroke patients n56 were diagnosed using imaging techniques and clinical examination along with and their laboratory results. The control group consisted of thirty healthy individuals. Blood samples of the patient group were obtained within the first 24 hours of stroke onset. Serum pentraxin levels of both groups were analyzed and their relationship with stroke risk factors evaluated. Results: A total of 86 people, 56 stroke patients and 30 healthy controls were included in the present study. Out of the participants, in both groups, 50 were female p1.000. No significant difference was determined between the groups in terms of age p0.226. The pentraxin value in the patient group was significantly lower than that in the control group p0.003. No significant difference between gender and presence of comorbidities in terms of PTX3 value p0.05 were present. Likewise, no significant correlation could be established between PTX3 value and National Institutes of Health Stroke Scale NIHSS and age in the patient group. Conclusion: Serum PTX3 can be used as a biomarker in acute stroke patients. However, it cannot be used as a predicator in determining prognosis during the acute period.

 Aims: Pentraxin 3 PTX3, an indicator of the inflammatory process, is an acute-phase protein AP with biphasic effect. In the present study, the relationship between PTX3 levels and stroke risk factors in stroke patients were analyzed. Methods: Acute stroke patients n56 were diagnosed using imaging techniques and clinical examination along with and their laboratory results. The control group consisted of thirty healthy individuals. Blood samples of the patient group were obtained within the first 24 hours of stroke onset. Serum pentraxin levels of both groups were analyzed and their relationship with stroke risk factors evaluated. Results: A total of 86 people, 56 stroke patients and 30 healthy controls were included in the present study. Out of the participants, in both groups, 50 were female p1.000. No significant difference was determined between the groups in terms of age p0.226. The pentraxin value in the patient group was significantly lower than that in the control group p0.003. No significant difference between gender and presence of comorbidities in terms of PTX3 value p0.05 were present. Likewise, no significant correlation could be established between PTX3 value and National Institutes of Health Stroke Scale NIHSS and age in the patient group. Conclusion: Serum PTX3 can be used as a biomarker in acute stroke patients. However, it cannot be used as a predicator in determining prognosis during the acute period.

 Aims: Pentraxin 3 PTX3, an indicator of the inflammatory process, is an acute-phase protein AP with biphasic effect. In the present study, the relationship between PTX3 levels and stroke risk factors in stroke patients were analyzed. Methods: Acute stroke patients n56 were diagnosed using imaging techniques and clinical examination along with and their laboratory results. The control group consisted of thirty healthy individuals. Blood samples of the patient group were obtained within the first 24 hours of stroke onset. Serum pentraxin levels of both groups were analyzed and their relationship with stroke risk factors evaluated. Results: A total of 86 people, 56 stroke patients and 30 healthy controls were included in the present study. Out of the participants, in both groups, 50 were female p1.000. No significant difference was determined between the groups in terms of age p0.226. The pentraxin value in the patient group was significantly lower than that in the control group p0.003. No significant difference between gender and presence of comorbidities in terms of PTX3 value p0.05 were present. Likewise, no significant correlation could be established between PTX3 value and National Institutes of Health Stroke Scale NIHSS and age in the patient group. Conclusion: Serum PTX3 can be used as a biomarker in acute stroke patients. However, it cannot be used as a predicator in determining prognosis during the acute period.

Makale detayları

Association of serum pentraxin 3 levels with comorbidities in acute ischaemic stroke patients

Yazarlar:

Filiz Demirdöğen

Yayıncı:

MediHealth Academy Yayıncılık

Ana Başlıklar:

Otonom Sinir Sistemi

Dergi:

Anatolian Current Medical Journal Vol.7 Issue 3, pp.358-362

Belge Tipi:

Makale

Yayın Tarihi:

5/2025

Belge Dili:

İngilizce

Document ID (Org No.):

2001349426

pISSN:

2718-0115

Stroke

pentraxin 3

NIHSS

comorbidity

Sayı

Makale detayları

Association of serum pentraxin 3 levels with comorbidities in acute ischaemic stroke patients

Yazarlar: Filiz Demirdöğen

Yayıncı: MediHealth Academy Yayıncılık

Ana Başlıklar: Otonom Sinir Sistemi

Dergi: Anatolian Current Medical Journal Vol.7 Issue 3, pp.358-362

Belge Tipi: Makale

Yayın Tarihi: 5/2025

Belge Dili: İngilizce

Document ID (Org No.): 2001349426

pISSN: 2718-0115

Stroke

pentraxin 3

NIHSS

comorbidity

Sayı

Yazarlar:

Filiz Demirdöğen

Yayıncı:

MediHealth Academy Yayıncılık

Ana Başlıklar:

Otonom Sinir Sistemi

Dergi:

Anatolian Current Medical Journal Vol.7 Issue 3, pp.358-362

Belge Tipi:

Makale

Yayın Tarihi:

5/2025

Belge Dili:

İngilizce

Document ID (Org No.):

2001349426

pISSN:

2718-0115